Updated: June 2026
Published by Physician Growth Partners
The pathology and laboratory services M&A market is at an inflection point. A surging pool of motivated strategic and financial buyers, a deeply fragmented industry, and a secular shift toward high-margin specialty diagnostics have converged to create an attractive seller environment.
If you own or operate an independent pathology practice, reference lab, or hospital outreach program, you are controlling an actively sought-out asset. Despite years of consolidation, the sector remains highly fragmented. National consolidators, private equity-backed platforms, and technology-driven acquirers are all competing aggressively for high-quality diagnostic lab businesses. This pathology and laboratory M&A guide gives independent lab owners and physician-operators the market data, recent transactions, and valuation benchmarks to help inform a decision if now is the right time to sell your business.
The U.S. pathology and laboratory services industry remains one of the most resilient and essential sectors in healthcare. The global diagnostic laboratory market was valued at approximately $142 billion in 2025 and is projected to reach nearly $223 billion by 2032, driven by aging demographics, rising chronic disease rates, and the continued growth of precision medicine, molecular diagnostics, and genomic testing.1, 2
Despite the industry’s scale, the market remains highly fragmented. While the five largest laboratory companies control roughly 50% of the market, the remaining share is spread across thousands of independent labs, pathology groups, specialty reference labs, and hospital outreach programs – creating a significant opportunity for consolidation and strategic acquisitions.3 Laboratory testing influences an estimated 70% of all physician clinical decisions, making diagnostic services a critical component of healthcare delivery.4 As demand continues to grow across oncology, autoimmune, genetic, and preventive testing, pathology and laboratory businesses remain highly attractive to private equity firms and strategic healthcare investors seeking durable, long-term growth.
Valuation in the laboratory and pathology sector is driven by a combination of revenue scale, specialty mix, payor composition, geographic density, and the defensibility of the practice’s testing menu. Labs with proprietary or semi exclusive testing capabilities, such as molecular oncology panels, hereditary screening, toxicology, or PFAS testing, represent some of the most sought after assets in the market today.
The following valuation ranges are intended for general market perspective only, as actual multiples vary based on specialty focus, growth, reimbursement mix, infrastructure, and overall deal quality. Lab companies with strong physician referral networks, scalable operations, and consistent organic growth typically attract the strongest buyer interest and premium valuations.
Current indicative valuation benchmarks in private M&A transactions:
| Lab Segment | Revenue Range | EBITDA Multiple |
|---|---|---|
| Small Independent Labs | $5M – $10M | 5.0x – 8.0x |
| Mid-Sized Regional Labs | $10M+ | 8.0x – 12.0x |
| High-Specialty & Niche Labs (e.g., genomics, PFAS, oncology) | — | 12.0x+ |
| Date | Target | Acquirer | Subsegment | Commentary |
|---|---|---|---|---|
| Feb 2025 | Select Lab Assets, Spectra Laboratories (Fresenius) | Quest Diagnostics | Hospital Outreach | Acquisition of dialysis-related outreach lab assets in New Jersey from Fresenius Medical Care. |
| Feb 2025 | Ambry Genetics | Tempus AI | Hereditary / Genomics | $600M; strengthens genomic data assets; adds hereditary cancer and rare disease testing to Tempus’ AI platform. |
| Mar 2025 | BioReference Health (Select Assets) | Labcorp | Hospital Outreach | Second BioReference acquisition by Labcorp; expands Southeast outreach presence in Mississippi. |
| Jul 2025 | Principle Diagnostics | Aqueous Health | Anatomic Pathology | Platform acquisition in Pennsylvania; establishes Aqueous Health’s anatomic pathology platform. |
| Aug 2025 | Clinical Testing Assets (Fresenius Medical Care) | Quest Diagnostics | Hospital Outreach | Acquisition of dialysis-related clinical testing assets; follows earlier Spectra Laboratories deal. |
| Sep 2025 | SouthEastern Pathology | Versant Diagnostics (Iron Path Capital) | Anatomic Pathology | CAP-accredited practice in Rome, GA; expands Versant’s digital pathology network into Georgia. |
| Mar 2026 | Lab Alliance of CNY (Crouse Health) | Labcorp | Hospital Outreach | Acquisition of 12 patient service centers; includes agreement to manage Crouse Health’s inpatient lab. |
| Mar 2026 | Exact Sciences | Abbott Laboratories | Precision Diagnostics | $21B landmark oncology deal; adds Cologuard, Oncotype DX, and Cancerguard to Abbott’s diagnostics portfolio. |
| Apr 2026 | Lab Products / IVD (CareDx) | EuroBio Scientific | IVD Manufacturing | $170M CareDx divestiture to refocus on core U.S. precision medicine testing services. |
| Apr 2026 | Eurofins E&E Business | UL Solutions | Specialty Testing | ~$670M; adds 44 labs across EMEA, Asia-Pacific, and U.S.; expands TIC capabilities in electrical safety and connected products. |
Market conditions rarely align this favorably across all dimensions simultaneously.
The laboratory and pathology sector continues to benefit from strong long term demand drivers, including an aging population, rising chronic disease prevalence, growth in oncology and molecular diagnostics, and increased adoption of automation, AI, and digital pathology technologies. Direct to consumer testing and personalized medicine are also creating new high margin growth opportunities.
At the same time, the industry faces ongoing pressure from labor shortages, reimbursement compression, and the rising capital requirements needed to invest in advanced testing platforms and infrastructure. These challenges disproportionately impact smaller independent operators.
PGP believes the laboratory M&A market remains highly active and competitive as large strategic buyers and private equity backed platforms continue pursuing acquisitions to expand specialty capabilities, geographic reach, and operational scale. With several major platforms nearing the end of their investment cycles, the market is expected to see increased recapitalization and acquisition activity over the coming years.
As buyer demand continues to outpace the supply of quality independent labs and pathology practices, valuations remain strong for businesses with differentiated testing capabilities, established referral relationships, and scalable infrastructure. For practice owners, this environment continues to create attractive opportunities for partnerships, growth capital, and strategic exits.
No obligation. Completely confidential. Typically 30 minutes.
Sources & Citations
Physician Growth Partners · This content is provided for informational purposes only and does not constitute legal, financial, or investment advice. All transaction data sourced as cited. © 2026 Physician Growth Advisors, LLC. All rights reserved.